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Abstract 
Background: The use of heparin is routine 
in endovascular procedures as a strategy in 
many centers that perform 
neurointerventional procedures to prevent 
occlusion of the catheters, but the use of 
this drug carries risks such as heparin-
induced thrombocytopenia. 
Objective: The purpose of this paper is to 
present a review of the literature. 
Material and methods: We conducted an 
extensive search and review of published 
papers about heparin and 
neurointerventional procedures.  
Results: The evidence in the literature is 
weak in relation to the use of heparin and 
the reduction of embolic effects associated 
with their use in endovascular procedures. 
Conclusion: The evidence on the use of 
heparin for the prevention of 
thromboembolic events in endovascular 
procedures are of low quality. There is 
insufficient evidence to conclude a potential 
benefit of heparin is useful in 
neurointerventional procedures. 
Prospective studies are needed to determine 
the effectiveness of heparin and avoid 
exposing patients to potential risks. 
Key words: heparin, neurointervention, 
neuroangiography, arterial catheters. 
Introduction 
During neurointerventional procedures, 
the use of catheters is a key step in the 
realization of the same, many international 
centers have traditionally used heparin 
infusion in order to prevent the formation 
of clots inside the devices; this potential 
thrombus can migrate to different parts of 
the body and cause injury. Complications 
of angiography and endovascular 
procedures, whichhave historically been 
used for the diagnosis and treatment of 
neurovascular diseases, have rarely been 
described in the literature.The most 
frequent complication reported in the 
literature is bruising during these 
procedures. Complications derived from 
angiographic procedures such as 
anaphylaxis and death account for 0.03 % 
and 0.06 %, respectively. 
Uses of heparin 
Heparin is the anticoagulant most 
frequently used in hospitalized patients in 








industrialized nations, there are applied 80 
million doses annually. 
The use of heparin is directed to 
maintain the integrity of catheters used in 
endovascular therapy. Currently the use of 
low molecular weight heparins is to prevent 
venous thromboembolism. Heparin is a 
mucopolysaccharide acid with variable 
molecular weight (4.000 to 40.000Da). 
Since 1935, high-molecular weights-
heparins have been usedto inhibit platelet 
activityalso. Heparin acts in vitroas 
antithrombininhibitor, activating the 
plasma, which disables the thrombin and 
factor Xa, then is metabolized byfast N-
desulfation after administration in the body. 
Usually heparin and similar products cause 
immunologically mediated 
thrombocytopenia, which usually occurs 
between the 5th and the 10th day. 
Usually the action of heparin is reversed 
by protamine sulfate, being the only agent 
that can stop heparin 
anticoagulation;complications of the use of 
protamine include systemic arterial 
hypotension, pulmonary arterial 
hypertension, bradycardia and oxygen 
consumption declination. 
Kaufmann et al. evaluated and analyzed 
the complications of diagnostic 
angiographyin 19826 consecutive patients, 
in that work thrombotic events were only 9 
(0.05%). Neurological complications 
occurred within the first 24 hours of 
angiography in 2.63% of patients. (1)It has 
been reported the presentation of 
intracerebral hemorrhage associated to 
endovascular procedures in which heparin 
was used. (2) The vasodilatory effects of 
heparin have been reported due to rapid 
administration, in the form of boluses. 
  
Therapeutic uses 
Venous thromboembolism: Heparin 
have beenextensively used for prevention of 
venous thromboembolism, a fixed dose of 
heparin of 5000 IU subcutaneously 
administered, every 8 hours reduce from 60 
to 70% the risk of venous thrombosis and 
decrease in mortality of 0.2% compared 
with control groups which evidenced a 
mortality of 0.7%. (5). 
Heparin has been used for many 
therapies along neurointervensionism 
evolution, such as aneurisms, (3, 
4)atherothrombotic vertebrobasilar 
occlusion, (5) as part of the reperfusion 
strategies for acute ischemic stroke, (6–11) 
for free-floating carotid thrombus, (12) 
cerebral venous sinus thrombosis, (9, 13) 
primary stent revascularization, (14) among 
others.Heparin is recommended during 
interventions due to the use of multiple 
intravascular tools in procedures that can 
last several hours. (3) Currently, 
neurointerventional procedures are 
performed under therapeutic heparinization 
- even in cases of ruptured aneurysms - to 
prevent thromboembolic events. (15) Due 
to the fact that many published multicenter 
studies about the use of anticoagulants have 
left the doses to the judgment of the 
investigators, these had notbeen reported. 
However, doses reported  by major 
monocenter studies (16–18) have been of 
initial boluses ranging from 3000 to 5000 
IU followed by 20-40 IU/kg/h continuously 
to maintain a monitored activated clotting 
time (ACT) between 200 and 300 seconds. 
(3) Protocols vary largely, and often 
comprise a standardized loading dose and 
no specified controls.  
In other kind of endovascular 
procedures, after a baseline ACT is 








generally given to a target prolongation of 
approximately 2 to 3 times the baseline 
value. Then heparin can be given 
continuously or as an intermittent bolus 
with hourly monitoring of ACT. (19) 
Only 69% of the surveyed members of 
The World Federation of Interventional 
and Therapeutic Neuroradiology 
(WFITN), uses heparin intraoperatively 
and in a continuous fashion. (3) The 
WFITN recommends a 5000 IU bolus, 
then 1000 IU/h continuously, with 
(monitored) ACT at about 200s. 
Nevertheless, there are many 
recommendations for heparin use outside 
the field of interventional neuroradiology 
that may be adaptable to the endovascular 
treatment of aneurisms. (20) The normally 
employed monitoring method is ACT, with 
guideline values > 200 s, most commonly 
between 250 and 300 seconds. (21) 
It is recommended to test the efficacy of 
the heparin regularly during the 
intervention. Loading and continuous doses 
must be adapted to the patient’s weight to 
rapidly attain and maintain ACT objectives 
during the intervention, which may take 
several hours (3).  
Preoperative oral anticoagulants are 
usually stopped 5 days before the 
intervention and replaced by heparin, 
which has the advantage of being easily 
antagonized in cases of intraoperative 
aneurism rupture. (3) Protamine sulfate 
dose for dose in the last hour will rapidly 
terminate heparinization. Some teams 
continue heparin infusion for 24–48 h, but 
the WFITN does not recommend pursuing 
anticoagulation postoperatively. (3) 
Any rationale for postoperative use of 
heparin is unclear. Indeed, no convincing 
clinical results have been published, and 
from a biological perspective it seems more 
pertinent to use antiplatelets. (3) On the 
other hand, there is insufficient evidence to 
support the use of either systemic or local 
thrombolysis in patients who have cerebral 
sinus venous thrombosis (CVST) according 
to European Federation of Neurologic 
Societies guidelines. 
Heparin use must be monitored. The 
effect of the heparin lasts for at least a few 
hours and patients usually need to be placed 
on antiplatelet therapy after the procedure. 
(15) 
In the resuscitation phase of any 
intracranial catastrophe, when the patient is 
receiving heparin, the presence of 
hemorrhage should elicit immediate 
heparin reversal (1 mg protamine for each 
100 units of heparin given) and low normal 
mean arterial pressure. (19) 
There are reports regard the use of 
heparin as an adjunct to 
neurointerventional procedures that can 
result in rapidly progressive intracerebral 
hemorrhages; (2) abciximab, aspirin, 
thienopyridinederivates are also reported. 
Careful management of coagulation is 
required to prevent thromboembolic 
complications during and after the 
neurointerventional procedure. (19) 
When a patient may be refractory to 
attempts to obtain adequate anticoagulation, 
(19) should be considered the switching 
from bovine to porcine heparin or vice 
versa. If antithrombin III deficiency is 
suspected, administration of fresh frozen 
plasma may be necessary to allow heparin to 
have its desired anticoagulant effect. (19) 
Thrombolytic therapy with recombinant 
tissue plasminogen activator (rt-PA) and 
secondary anticoagulation with heparin to 
prevent rethrombosis in acute stroke 
patients has been shown to be beneficial in 








complication of this therapy is secondary 
postischemic symptomatic intracranial 
hemorrhage (SICH), (23) which can be 
devastating. It is necessary to detect 
microbleeds (MBs) or hemorrhagic 
transformation (HT) early and accurately, 
and to institute rapid treatment decision-
making according to neuroimaging findings 
to prevent development of a hemorrhage-
prone state and improve neurologic 
recovery. (24–26) 
Other complications derived from the 
use of heparin, is the heparin-related ICH, 
which is rare and data are sparse regarding 
appropriate treatment. One reasonable 
approach would be to reverse heparin with 
IV protamine sulfate at a dose of 1 mg to 1.5 
mg per 100 units of heparin with a 
maximum dose of 50 mg. (27,28) 
Heparin-induced thrombocytopenia 
(HIT) is a rare but important adverse event 
for heparin anticoagulation. (19)The 
incidence of HIT in neurological patients 
continues to increase with expansion of 
indication for neurointerventional 
procedures. The pathophysiology of HIT is 
related to a hypersensitivity reaction against 
complex platelet factor 4. (29) The 
diagnosis is mostly clinical and is often 
confirmed by laboratory testing. (29) 
Patients with HIT have a higher rate of 
thromboembolic complications, both 
arterial and venous, and with worse 
neurological outcomes at the time of 
discharge. Early diagnosis and heparin 
cessation are essential in the management of 
those patients. Both immediate and 
prolonged alternative anticoagulation are 
necessary. Understanding of the 
mechanism of action, indication and drug 
interaction of the alternative anticoagulants 
(direct thrombin inhibitors, fondaparinux 
and danaparoid) and warfarin is essential 
during management of these patients. (29) 
Often, the thromboembolic risks in the 
endovascular treatment of aneurisms are 
lesser than those found in stenting or 
extracranial angioplasty (3).  
Conclusion 
Clearly, heparin is not an innocuous 
molecule; indications for its use should be 
clearly stated in individualized patients, 
assessing factors such as comorbidities, age, 
allergic states, time for use, and clinical 
evolution. However heparin may be useful 
only in cases where the patient has 
prothrombotic states. As stated previously, 
clinical studies had lead dosage to author’s 
criteria, thus there is not a widely assessed 
dosage for heparin, especially in patients 
with neurovascular conditions. It is needed 
more unification for indication, dosage and 
cessation criteria. Prospective studies are 
needed to determine the effectiveness of 
heparin and avoid exposing patients to 
potential risks. 
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